Professional History
Syneos Health: Business Unit Head, SVP Managing Director, Morrisville: 05/2021 - 07/2024
3 Years Business Unit Leadership
3 Years Business Unit Leadership
Liquidia Technologies: VP, R&D Project and Portfolio Management, Morrisville, NC: 07/2019 - 01/2021
18 Months Biotech Operations
18 Months Biotech Operations
Eli Lilly & Company: Senior Director, Thoracic Oncology Business Unit, Indianapolis, IN: 09/2016 - 12/2017
28 Years Integrated Drug Development, Product and Portfolio Management
28 Years Integrated Drug Development, Product and Portfolio Management
|
|
History of Implementing Key Deliverables
Syneos Health: Executive leadership accountability for strategic standalone business unit with a Top 10 Pharma partner. Created centralized business unit operations and partnership management function to drive consistency in partnership processes, portfolio delivery, quality, KPI reporting and partnership communications resulting in increased utilization of billable roles. Improved business unit profitability by driving a 4% change in resource utilization and gross margin over a period of five months and maintaining or exceeding that level of utilization for 24 months. Expanded business outside of the traditional therapeutic area, generating over $150m in new gross awards. Led the resolution of over $18 Million in non-billable change orders via unit negotiations with partners and a wholesale financial re-education of all business unit staff, leading to recovery of $10 Million.
Liquidia Technologies: Led the successful integration of RareGen, LLC including financial, legal, HR, IT, and sales force compliance transition activities with no disruption of corporate deliverables. Modified internal compliance structure and responsibilities; served as the Compliance Officer for RareGen, LLC. Led the development of an integrated commercial launch readiness plan for the company's lead asset, inclusive of sales and marketing, medical affairs, healthcare and financial compliance roadmaps, government contracting activities, quality, commercial supply plan and a multi-year IT strategy required for successful launch. Working with industry experts, led the research and implementation of an FDA acceptable human factors strategy.
Eli Lilly & Company: Strategically led the integration of 70+ new capabilities and technologies into the Lilly cross-functional drug development operating system across four major work streams, ultimately resulting in a cross-portfolio average timeline reduction of 3.7 years between FHD – FL. While serving as the COO for the Lilly Chorus organization, cost-effectively managed a $25 million budget while overseeing clinical operations, portfolio governance, third-party procurement and contracting. Built and sustained mutually beneficial partnerships with three VC sponsors focused on results-generating asset selection, joint governance body decision-making, periodic reporting, and establishing new Chorus business processes to actively support the development of assets external to Lilly.
